CURRICULUM VITAE – EUROPEAN FORMAT

PERSONAL INFORMATION

• Scopus ID: 57212659377

• ORCID: 0000-0003-2726-1895

• e-mail: ugo.chianese@unicamillus.org

CURRENT POSITION

Tenure-track Researcher (RTT) at Saint Camillus International University of Health Sciences – UniCamillus University, Via di Sant'Alessandro 8, 00131 Rome, Italy.

PROFESSIONAL EXPERIENCE

• **2023**: Type A Researcher (RTDA) with a three-year contract plus two-year extension at the University of Campania "Luigi Vanvitelli". Activities include research, teaching, supplementary teaching, and student services within the framework of the PNRR research program "National Center for Gene Therapy and RNA-based Drugs", Department of Precision Medicine, SSD MEDS-02/A.

• **2022**: Research Fellow (three-year contract starting 01/02/2022) at the University of Campania "Luigi Vanvitelli", Department of Precision Medicine, SSD MEDS-02/A, project: "Network of epi-medicine and precision oncology".

• **2022**: Member of the innovative startup Circe S.r.l., an academic spin-off funded by the Campania Region under the STARTUP CAMPANIA 2020 program, established on 17/05/2022. The company operates in the field of advanced diagnostics, with a focus on the identification and validation of novel clinically applicable biomarkers to improve early diagnosis and prognosis of oncological diseases (GSD 06/MEDS-02, SSD MEDS-02/A).

• **2020**: Research activity in oncology aimed at the identification of diagnostic and prognostic biomarkers at the Princess Máxima Center for Pediatric Oncology BV, Utrecht, Netherlands.

EDUCATION AND TRAINING

• **2022**: PhD in Translational Medicine, GSD 06/MEDS, Department of Precision Medicine, University of Campania "Luigi Vanvitelli", Naples, Italy. Dissertation: "Epigenetics in Prostate Cancer". Graduated with honors.

• 2**018**: Master's Degree in Pharmacy, Department of Experimental Medicine – Section of Pharmacology and Toxicology, University of Campania "Luigi Vanvitelli". Thesis: "Role of the endocannabinoid system in sensory alterations induced by vitamin D deficiency". Qualified as a licensed pharmacist after passing the State Examination (Session II, 2018).

TEACHING ACTIVITY

• Lecturer in **General Pathology (SSD MEDS-02/A)** at the University of Campania "Luigi Vanvitelli", degree programs in Healthcare Assistance and Medical Radiology Techniques, Academic years 2023–2024; 2024–2025; 2025–2026. Total of 7 ECTS credits.

• Lecturer in the **PhD Course in Translational Medicine**, Doctoral School in Life Sciences, for PhD candidates of cycles XXXIX–XL, with teaching activity on "Metabolic reprogramming: epigenetic landscape in cancer disease" (SSD MEDS-02/A), Academic years 2024–2025; 2025–2026. Total of 4 ECTS credits.

SCIENTIFIC OUTPUT

• Indexed publications: 24
• H-index: 12
• Citations: 404

Highlighted role as **first** or **co-first author**

1. **Ugo Chianese**, Chiara Papulino, Gerardo Saggese, Ahmad Ali, Marianna Ciotola, Enza Lonardo, Mirko Cortese, Gregorio Favale, Annabella Di Mauro, Danila La Gioia, Valentina Golino, Eduardo Sommella, Pietro Campiglia, Renato Franco, Fortunato Ciardiello, Ferdinando De Vita, Vincenzo Carafa, Lucia Altucci, Rosaria Benedetti. Glycolytic heterogeneity drives metabolic-targeted therapy in pancreatic ductal adenocarcinoma**.** Signal Transduct Target Ther. 2026 **Impact Factor 81.2**
2. Benedetti R.†, **Chianese U**.†, Papulino C., Scisciola L., Cortese M., Formisano P., Del Gaudio N., Cabaro S., D'Esposito V., Pesapane A., Conte M., Signoriello G., Barbieri M., Altucci L., Paolisso G. Unlocking the power of empagliflozin: Rescuing inflammation in hyperglycaemia- exposed human cardiomyocytes through comprehensive multi-level analysis. Eur J Heart Fail. 2025 **Impact Factor 10.3**
3. Papulino C.†, **Chianese U**.†, Ali A., Favale G., Tuccillo C., Ciardiello F., Di Mauro A., Mignogna C., Ferrara G., Budillon A., Megchelenbrink W.L., Del Gaudio N., Conte M., Merciai F., Campiglia P., Altucci L., Carafa V., Sommella E., Benedetti R. Inverse FASN and LDHA correlation drives metabolic resistance in breast cancer. Journal of Translational Medicine. 2024 **Impact Factor 9.7**
4. Nurcis J, Foglia B, Rosso C, Provera A, Vecchio C, Maggiora M, Gambella A, **Chianese U**, Bocca C, Caviglia GP, Benedetti R, Novo E, Bossi F, Doto F, Kowalik MA, Caddeo A, Carucci P, Gaia S, Romagnoli R, Menconi A, Tusa I, Rovida E, Perra A, Bugianesi E, Altucci L, Albano E, Parola M, Sutti S, Cannito S. The role of OSM/OSMRβ axis in shaping the tumor microenvironment favoring MASLD-related HCC immune evasion. Hepatology. 2026 Mar 4 **Impact Factor 18.0**
5. Carullo G., Rossi R., Giudice V., Pezzotta A., **Chianese U**., Scala P., Carbone S., Fontana A., Panzeca G., Pasquini S., et all. Development of Epigenetic Modifiers with Therapeutic Potential in FMS-Related Tyrosine Kinase 3/Internal Tandem Duplication (FLT3/ITD) Acute Myeloid Leukemia and Other Blood Malignancies. ACS Pharmacol Transl Sci. 2024 **Impact Factor 4.0**
6. **Chianese U**.†, Papulino C.†, Ali A., Ciardiello F., Cappabianca S., Altucci L., Carafa V. and Benedetti R. FASN multi-omic characterization reveals metabolic heterogeneity in pancreatic and prostate adenocarcinoma. Journal of Translational Medicine. 2023. **Impact Factor 9.7**
7. Scisciola L†, **Chianese U**†, Caponigro V†, Basilicata MG, Salviati E, Altucci L, Campiglia P, Paolisso G, Barbieri M, Benedetti R, Sommella E.Multi-omics analysis reveals attenuation of cellular stress by empagliflozin in high glucose-treated human cardiomyocytes. Journal of Translational Medicine. 2023 **Impact Factor 9.7**
8. **Chianese U**†, Papulino C†, Megchelenbrink W, Tambaro FP, Ciardiello F, Benedetti R, Altucci L. Epigenomic machinery regulating pediatric AML: clonal expansion mechanisms, therapies, and future perspectives. Semin Cancer Biol. 2023 **Impact Factor 20.3**
9. Varghese B, **Chianese U**, Capasso L, Sian V, Bontempo P, Conte M, Benedetti R, Altucci L, Carafa V, Nebbioso. SIRT1 activation promotes energy homeostasis and reprograms liver cancer metabolism. A. Journal of Translational Medicine 2023 **Impact Factor 9.7**
10. Martins-Lima C, **Chianese U**, Benedetti R, Altucci L, Jerónimo C, Correia MP. Tumor microenvironment and epithelial-mesenchymal transition in bladder cancer: Cytokines in the game? Front Mol Biosci. 2023 **Impact Factor 4.4**
11. Sobinoff A.P., Di Maro S., Low R.R.J, Benedetti R., Tomassi S., D'Aniello A., Russo R., Baglivo I., **Chianese U.**, Pedone P.V., et all. Irreversible inhibition of TRF2 recruiting functions by a covalent cyclic peptide induces telomeric replication stress in cancer cells. Cell Chemical Biology. 2023 **Impact Factor 9.0**
12. MiR-423-5p is a metabolic and growth tuner in hepatocellular carcinoma via MALAT-1 and mitochondrial interaction. Bocchetti M, Cossu AM, Porru M, Ferraro MG, Irace C, Tufano R, Vitale G, Misso G, Amodio N, Scrima M, Simeone I, Ceccarelli M, **Chianese U**, Altucci L, Desiderio V, Regad T, Caraglia M, Zappavigna S. J Exp Clin Cancer Res. 2025 Sep 30;44(1):270. doi: 10.1186/s13046-025-03524-2. **Impact Factor 14.3**
13. **Chianese U**†, Papulino C†, Passaro E, Evers TM, Babaei M, Toraldo A, De Marchi T, Niméus E, Carafa V, Nicoletti MM, Del Gaudio N, Iaccarino N, Randazzo A, Rotili D, Mai A, Cappabianca S, Mashaghi A, Ciardiello F, Altucci L, Benedetti R. Histone lysine demethylase inhibition reprograms prostate cancer metabolism and mechanics. Mol Metab. 2022 **Impact Factor 6.6**
14. Ali A†, **Chianese U**†, Papulino C, Toraldo A, Abakar MEA, Passaro E, Cennamo R, Del Gaudio N, Altucci L, Benedetti R. Metabolic Pathways as a Novel Landscape in Pancreatic Ductal Adenocarcinoma. Cancers (Basel). 2022 **Impact Factor 4.8**
15. Scisciola L, Benedetti R, **Chianese U**, Fontanella RA, Del Gaudio N, Marfella R, Surina, Altucci L, Barbieri M, Paolisso G. The pivotal role of miRNA-21 in myocardial metabolic flexibility in response to short- and

long-term high glucose treatment: Evidence in human cardiomyocyte cell line. Diabetes Res Clin Pract. 2022 **Impact Factor 4.6**

16. Fioravanti R, Rodriguez V, Caroli J, **Chianese U**, Benedetti R, Di Bello E, Noce B, Zwergel C, Corinti D, Viña D, Altucci L, Mattevi A, Valente S, Mai A. Heterocycle-containing tranylcypromine derivatives endowed with high anti-LSD1 activity. J Enzyme Inhib Med Chem. 2022 **Impact Factor 5.3**
17. Benedetti R, Benincasa G, Glass K, **Chianese U**, Vietri MT, Congi R, Altucci L, Napoli C. Effects of novel SGLT2 inhibitors on cancer incidence in hyperglycemic patients: a meta-analysis of randomized clinical trials. Pharmacol Res. 2022 **Impact Factor 12.2**
18. Montella M., Ciani G., Granata V., Fusco R., Grassi F., Ronchi A., Cozzolino I., Franco R., Zito Marino F., Urraro F., Monti R., Sirica R., Savarese G., **Chianese U**., Nebbioso A., Altucci L., et all. Preliminary Experience of Liquid Biopsy in Lung Cancer Compared to Conventional Assessment: Light and Shadows. J Pers Med. 2022 **Impact Factor 3.0**
19. Passaro E, Papulino C, **Chianese U,** Toraldo A, Congi R, Del Gaudio N, Nicoletti MM, Benedetti R, Altucci L. HDAC6 Inhibition Extinguishes Autophagy in Cancer: Recent Insights. Cancers (Basel). 2021 **Impact Factor 4.8**
20. Benedetti R, Papulino C, Sgueglia G., **Chianese U**., De Marchi T., Iovino F., Rotili D., Mai A., Niméus E., Dell' Aversana C., Altucci L. (2021). Regulatory Interplay between miR-181a-5p and Estrogen Receptor Signaling Cascade in Breast Cancer. Cancers. 2021 **Impact Factor 4.8**
21. Linciano P, Pinzi L, Belluti S, **Chianese U**, Benedetti R, Moi D, Altucci L, Franchini S, Imbriano C, Sorbi C, Rastelli G. (2021). Inhibitors of histone deacetylase 6 based on a novel 3-hydroxy-isoxazole zinc binding group. J Enzyme Inhib Med Chem. 2021 **Impact Factor 5.3**
22. Linciano P, Benedetti R, Pinzi L, Russo F, **Chianese U**, Sorbi C, Altucci L, Rastelli G, Brasili L, Franchini S. (2021) Investigation of the effect of different linker chemotypes on the inhibition of histone deacetylases (HDACs). Bioorg Chem. 2021 **Impact Factor 5.1**
23. Papulino C†., **Chianese U**†., Nicoletti M. M., Benedetti R., Altucci L. (2020). Preclinical and Clinical Epigenetic-Based Reconsideration of Beckwith-Wiedemann Syndrome. Frontiers in Genetics. 2020 **Impact Factor 3.0**
24. Benedetti R., Dell'Aversana C., De Marchi T., Rotili D., Liu N.Q., Novakovic B., Boccella S., Di Maro S., Cosconati S., Baldi A., Niméus E., Schultz J., Höglund U., Maione S., Papulino C., **Chianese U.,** Iovino F., Federico A., Mai A., Stunnenberg H.G., Nebbioso A., Altucci, L. (2019). Inhibition of Histone Demethylases LSD1 and UTX Regulates ERα Signaling in Breast Cancer. Cancers. 2019 **Impact Factor 4.8**

SUPERVISION AND MENTORING

Tutoring and supervision activities for PhD students in Translational Medicine (GSD 06/MEDS) at the University of Campania "Luigi Vanvitelli".

CONFERENCES AND SEMINARS

• 2026 – **Invited Speaker**, EC-SIBBM International Congress Pre-Meeting, Siena
• 2025 – **Selected Speaker,** SIBBM International Congress, Naples
• 2023 – **Selected Speaker**, CLEPIC – Clinical Epigenetics International Conference, Szczecin (Poland)
• 2024 – **Selected Speaker**, Italian Pancreatic Cancer Symposium (IPCC), Padua
• 2025 – **Selected Speaker**, CIRLAM – Centre for Interdisciplinary Research in Language and Medicine, Naples
• 2024 – **Selected Speaker**, PRESCRIPTOMICS & PRECISION MEDICINE, Lisbon (Portugal)
• 2023 – **Selected Speaker**, 35th AICC – Translational and Precision Medicine, L'Aquila, Italy
• 2023 – **Selected Speaker**, SIPMeT – Italian Society of Pathology and Translational Medicine, Parma, Italy. Presentation: Single-cell and Spatial Transcriptomics reveal metabolic heterogeneity in pancreatic cancer
• 2025 – **Selected Speaker**, International Webinar, International Society for Molecular and Clinical Epigenetics (iSMOCLEP). Presentation: Targeted Therapy in PDAC: A Metabolic Heterogeneity-Based Approach
• 2025 – **Organizer**, EC-SIBBM Pre-meeting, Naples, Italy
• 2026 – **Member** of the Scientific Committee of SIPMeT, involved in the planning and scientific evaluation of the society's initiatives

AWARDS AND RECOGNITION

• 2025 – **Francesca Martini Prize (Best Oral Presentation)**, SIBBM International Congress, Naples, Italy.
• 2025 – **Best Paper Award**, CIRLAM – Centre for Interdisciplinary Research in Language and Medicine, Naples, Italy.
• 2024 – **Travel Grant**, Italian Pancreatic Cancer Symposium (IPCC), Padua, Italy.
• 2023 – **Travel Grant**, CLEPIC – Clinical Epigenetics International Conference, Szczecin, Poland.

BOOK CHAPTERS / CONTRIBUTIONS

• Cancer Epigenetics – "Current Preclinical Applications of Pharmaco-Epigenetics in Cardiovascular Diseases", December 2023. Authors: Chiara Papulino, **Ugo Chianese**, Lucia Scisciola, Ahmad Ali, et al. DOI: 10.1007/978-3-031-42365-9_9.

• Cell Death Regulation in Pathology – "In-Depth Exploration of Radiation-Induced Cell Death Mechanisms in Tumor". Authors: Chiara Papulino, Marco Crepaldi, Gregorio Favale, **Ugo Chianese**, et al.

• Role of Sex and Gender in Aging and Longevity – Chapter 6: "Role of genetics and hormones in the differences in longevity between men and women". Authors: Elena Ciaglia, Lucia Altucci, **Ugo Chianese**, Valentina Lopardo, et al. ISBN: 9780443273995.

• In-Depth Exploration of Radiation-Induced Cell Death Mechanisms in Tumor, 25 August 2025. Authors: Chiara Papulino, Marco Crepaldi, Gregorio Favale, **Ugo Chianese**, et al. DOI: 10.5772/intechopen.1009748.

THIRD MISSION / TECHNOLOGY TRANSFER

• Co-founder of the innovative startup Circe S.r.l., an academic spin-off of the Department of Precision Medicine, University of Campania "Luigi Vanvitelli". The company operates in the field of advanced diagnostics, with a strong focus on the identification and validation of novel clinically applicable biomarkers aimed at improving early diagnosis and prognosis of oncological diseases within GSD 06/MEDS-02, SSD MEDS-02/A. The company was founded in Naples in 2022 and has achieved the following participations and awards:
• Participation in the "Marzotto 2031" award, receiving in-kind services worth €30,000 from the Bio4Dreams Business Incubator, Milan.
• Participation in the "Start-Cup Campania 2022" competition, achieving second place with a prize of €3,500, and additionally receiving the "Contamination" award worth €500 in the same competition.
• CIRCE S.r.l., startup of the Department of Precision Medicine of the University of Campania "Luigi Vanvitelli", in relation to the call "Research Award with Industrial Impact 2023" issued under DR 114/2023.
• Funding from the Campania Region of approximately €80,000 for research and industrial development (Campania Start Up 2020 – PO FESR 2014–2020 Axis 1 OS 1.1, Regional Decree No. 10 dated 02/03/2022).
• Winner of the "America Innovation Award", which included a scholarship for participation in the Master's program "Leadership for International Relations and Made in Italy", and an award ceremony held at the Italian Chamber of Deputies on 05/05/2023.
• Winner of the University of Campania "Luigi Vanvitelli" call "Research Award with Industrial Impact 2022", obtaining a €25,000 research grant.
• Winner of "Innovation Village 2023", receiving a special award from EIT Health InnoStars in services and the "Associazione Donne 4.0" award for addressing gender inequality.
• Award for Best Startup of the University of Campania "Luigi Vanvitelli" 2023 at the Vanvitelli Day for spin-offs.
• Winner of the University of Campania "Luigi Vanvitelli" call "Research Award with Industrial Impact 2023", obtaining a €25,000 research grant.
• Top Ten Project, China Oversees Talent Competition 2024, held at the Apple Developer Academy of the University of Naples Federico II.

SCIENTIFIC SKILLS

• Study of gene expression profiles in oncology aimed at identifying diagnostic and prognostic biomarkers, improving patient stratification, and developing personalized therapeutic strategies through an integrated

multi-omics approach.

• Expertise in characterizing tumor heterogeneity and defining cellular subpopulations, with particular focus on the dynamics of the tumor microenvironment.

• Ability to correlate gene, protein, and metabolic expression levels to identify therapeutic targets and relevant biological pathways.

• Experience in identifying tumor subgroups and defining molecular signatures associated with specific clinical phenotypes.

• Integration of complex data from different omics platforms for the identification of biomarkers and key regulatory nodes.

• In-depth knowledge of epigenetic mechanisms, including DNA methylation alterations and histone modifications, and their role in transcriptional regulation in cancer.

• Competence in the study of tumor metabolism and cellular signaling networks to understand mechanisms of disease progression and therapeutic resistance.

LANGUAGE SKILLS

English: good written and spoken knowledge (intermediate level).